Table 4.

Results of fixed effect and random effects NMA of different pharmacological thromboprophylaxis interventions versus no thromboprophylaxis

	Fixed effect odds ratio (95% CrI)	Random effects odds ratio (95% CrI)	Odds ratio (95% PrI)	Prob. Best
Clinically detected DVT (symptomatic):
LMWH	0.45 (0.22‐0.89)	0.40 (0.12‐0.99)	0.41 (0.05‐2.31)	0.09
Fondaparinux	0.11 (0.01‐0.60)	0.10 (0.01‐0.94)	0.10 (0.00‐1.46)	0.91
None	‐	‐	‐	0.00
Asymptomatic DVT (proximal segment):
LMWH	0.22 (0.05‐0.71)	0.21 (0.04‐0.82)	0.21 (0.02‐1.34)	0.63
Fondaparinux	0.29 (0.03‐2.35)	0.28 (0.02‐3.42)	0.28 (0.01‐4.49)	0.36
None	‐	‐	‐	0.01
Asymptomatic DVT (distal):
LMWH	0.69 (0.47‐1.01)	0.69 (0.43‐1.12)	0.69 (0.29‐1.62)	0.00
Fondaparinux	0.11 (0.04‐0.27)	0.11 (0.03‐0.35)	0.11 (0.03‐0.42)	1.00
None	‐	‐	‐	0.00
Asymptomatic DVT (all):
LMWH	0.57 (0.42‐0.77)	0.57 (0.39‐0.82)	0.57 (0.28‐1.12)	0.00
Fondaparinux	0.14 (0.07‐0.27)	0.14 (0.05‐0.31)	0.14 (0.05‐0.38)	1.00
None	‐	‐	‐	0.00
Pulmonary embolism:
LMWH	0.30 (0.07‐0.96)	0.17 (0.01‐0.88)	0.18 (0.00‐1.79)	0.74
Fondaparinux	0.64 (0.05‐7.26)	0.47 (0.01‐9.54)	0.48 (0.01‐17.53)	0.25
None	‐	‐	‐	0.01
Major bleeding:
LMWH	1.60 (0.14‐25.67)	1.45 (0.08‐32.17)	1.46 (0.06‐42.87)	0.37
Fondaparinux	14380 (0.48‐9.9E14)	8422 (0.32‐1.3E14)	8421 (0.29‐1.3E14)	0.03
None	‐	‐	‐	0.59
Clinically relevant DVTa
LMWH	0.43 (0.22‐0.79)	0.40 (0.16‐0.85)	0.40 (0.07‐1.76)	0.22
Fondaparinux	0.25 (0.07‐0.82)	0.23 (0.03‐1.36)	0.23 (0.02‐ 2.11)	0.77
None	‐	‐	‐	0.01
Any VTE:
LMWH	0.53 (0.41‐0.67)	0.52 (0.37‐0.71)	0.52 (0.23‐1.12)	0.00
Fondaparinux	0.14 (0.07‐0.25)	0.13 (0.05‐0.30)	0.13 (0.04‐0.39)	1.00
None	‐	‐	‐	0.00

Abbreviations: CrI, credible interval; PrI, predictive interval.

^aClinically relevant DVT was defined as the cumulative figure of any symptomatic OR asymptomatic proximal DVT.